Drug Profile
Amlodipine/simvastatin
Alternative Names: Fixed-dose combination of delayed-release amlodipine and immediate-release simvastatin - HanAll Biopharma; HL-007; Simvastatin/amlodipine - HanAll BiopharmaLatest Information Update: 04 Aug 2015
Price :
$50
*
At a glance
- Originator HanAll Biopharma
- Class Antihyperlipidaemics; Antihypertensives; Dihydropyridines; Naphthalenes
- Mechanism of Action Calcium channel antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hyperlipidaemia; Hypertension
Most Recent Events
- 04 Aug 2015 No recent reports on development identified - Phase-II for Hyperlipidaemia in South Korea (PO)
- 04 Aug 2015 No recent reports on development identified - Phase-II for Hypertension in South Korea (PO)
- 04 Aug 2015 No recent reports on development identified - Preclinical for Hyperlipidaemia in USA (PO)